JP2024539123A5 - - Google Patents

Info

Publication number
JP2024539123A5
JP2024539123A5 JP2024523575A JP2024523575A JP2024539123A5 JP 2024539123 A5 JP2024539123 A5 JP 2024539123A5 JP 2024523575 A JP2024523575 A JP 2024523575A JP 2024523575 A JP2024523575 A JP 2024523575A JP 2024539123 A5 JP2024539123 A5 JP 2024539123A5
Authority
JP
Japan
Application number
JP2024523575A
Other languages
Japanese (ja)
Other versions
JP2024539123A (ja
JPWO2023073526A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2022/060189 external-priority patent/WO2023073526A1/en
Publication of JP2024539123A publication Critical patent/JP2024539123A/ja
Publication of JP2024539123A5 publication Critical patent/JP2024539123A5/ja
Publication of JPWO2023073526A5 publication Critical patent/JPWO2023073526A5/ja
Pending legal-status Critical Current

Links

JP2024523575A 2021-10-25 2022-10-24 アデノ随伴ウイルス(aav)送達を改善する方法 Pending JP2024539123A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163271487P 2021-10-25 2021-10-25
US63/271,487 2021-10-25
PCT/IB2022/060189 WO2023073526A1 (en) 2021-10-25 2022-10-24 Methods for improving adeno-associated virus (aav) delivery

Publications (3)

Publication Number Publication Date
JP2024539123A JP2024539123A (ja) 2024-10-28
JP2024539123A5 true JP2024539123A5 (https=) 2025-10-31
JPWO2023073526A5 JPWO2023073526A5 (https=) 2025-10-31

Family

ID=84283163

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024523575A Pending JP2024539123A (ja) 2021-10-25 2022-10-24 アデノ随伴ウイルス(aav)送達を改善する方法

Country Status (5)

Country Link
US (1) US20250235554A1 (https=)
EP (1) EP4422613A1 (https=)
JP (1) JP2024539123A (https=)
CN (1) CN118043039A (https=)
WO (1) WO2023073526A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2024071362A1 (https=) * 2022-09-30 2024-04-04
WO2025101959A1 (en) * 2023-11-08 2025-05-15 Renbio, Inc. Plasmid dna constructs for peptide hormone expression
WO2025250457A1 (en) * 2024-05-28 2025-12-04 University Of Rochester Enhanced brain transduction by gene therapeutics
CN118743768A (zh) * 2024-06-13 2024-10-08 浙江大学 一种血小板-aav包装复合体及其制备方法和应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
WO1998033917A1 (en) 1994-11-14 1998-08-06 The Ludwig Institute For Cancer Research Vascular endothelial growth factor c (vegf-c) protein and gene, mutants thereof, and uses thereof
US6001650A (en) 1995-08-03 1999-12-14 Avigen, Inc. High-efficiency wild-type-free AAV helper functions
US6410300B1 (en) 1998-01-12 2002-06-25 The University Of North Carolina At Chapel Hill Methods and formulations for mediating adeno-associated virus (AAV) attachment and infection and methods for purifying AAV
EP1751275B1 (en) 2004-06-01 2017-08-16 Avigen, Inc. Compositions and methods to prevent aav vector aggregation
SI2548560T1 (sl) 2005-06-23 2015-12-31 Isis Pharmaceuticals, Inc. Sestavki in postopki za moduliranje izrezovanja smn2
US9415121B2 (en) 2008-12-19 2016-08-16 Nationwide Children's Hospital Delivery of MECP2 polynucleotide using recombinant AAV9
PT3305302T (pt) 2009-06-17 2018-12-14 Biogen Ma Inc Composições e métodos de modulação de excisões de smn2 em um sujeito
EP2964270A4 (en) * 2013-02-21 2017-03-22 University Of Rochester Methods for evaluating brain-wide paravascular pathway for waste clearance function and methods for treating neurodegenerative disorders based thereon
LT3702466T (lt) 2013-08-27 2023-02-27 Research Institute At Nationwide Children's Hospital Produktai ir būdai, skirti šoninės amiotrofinės sklerozės gydymui
US9585971B2 (en) 2013-09-13 2017-03-07 California Institute Of Technology Recombinant AAV capsid protein
EP3245221A4 (en) 2015-01-16 2018-06-13 Voyager Therapeutics, Inc. Central nervous system targeting polynucleotides
KR102423442B1 (ko) 2015-12-11 2022-07-20 캘리포니아 인스티튜트 오브 테크놀로지 아데노-관련 바이러스를 지시하기 위한 타겟팅 펩타이드
MX2020004830A (es) 2017-11-08 2020-11-11 Avexis Inc Medios y metodo para preparar vectores virales y usos de los mismos.
TW202015742A (zh) 2018-05-15 2020-05-01 美商航海家醫療公司 投遞腺相關病毒(aav)之組成物和方法
EP3793615A2 (en) 2018-05-16 2021-03-24 Voyager Therapeutics, Inc. Directed evolution of aav to improve tropism for cns
US20210207167A1 (en) 2018-05-16 2021-07-08 Voyager Therapeutics, Inc. Aav serotypes for brain specific payload delivery
US20210277418A1 (en) 2018-08-03 2021-09-09 Voyager Therapeutics, Inc. Aav variants with enhanced tropism
US12311035B2 (en) * 2018-10-04 2025-05-27 University Of Rochester Glymphatic delivery by manipulating plasma osmolarity

Similar Documents

Publication Publication Date Title
JP2024540972A5 (https=)
BR102022025291A2 (https=)
BR102023014872A2 (https=)
BR102023012440A2 (https=)
BR102023010976A2 (https=)
BR102023009641A2 (https=)
BR102023008688A2 (https=)
BR102023007252A2 (https=)
BR102023005164A2 (https=)
BR102023001877A2 (https=)
BR102023000289A2 (https=)
BR102022026909A2 (https=)
BR202022009269U2 (https=)
BR202022005961U2 (https=)
BR202022001779U2 (https=)
BR202022000931U2 (https=)
BY13149U (https=)
BY13159U (https=)
BY13140U (https=)
BY13141U (https=)
BY13142U (https=)
BY13143U (https=)
BY13144U (https=)
BY13145U (https=)
BY13168U (https=)